Pharmacoeconomic evaluation of testing for angiotensinconverting enzyme genotype before starting ß-hydrocy-ß-methylglutaryl coenzyme A reductase inhibitor therapy in men
Publication date
2004
Authors
Maitland-van der Zee, Anke Hilse
Klungel, Olaf H.
Stricker, B.H.Ch.
Veenstra, D.L.
Kastelein, J.J.P.
Hofman, A.
Witteman, J.C.M.
Leufkens, Bert
van Duijn, C.M.
De Boer, Anthonius
Editors
Advisors
Supervisors
DOI
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Keywords
Farmacie/Biofarmaceutische wetenschappen (FARM), Epidemiology, Farmacie(FARM), Biomedische technologie en medicijnen, Ziekenhuisstructuur en organisatie van de gezondheidszorg, Public Health, SDG 3 - Good Health and Well-being
Citation
Maitland-van der Zee, A H, Klungel, O H, Stricker, B H C, Veenstra, D L, Kastelein, J J P, Hofman, A, Witteman, J C M, Leufkens, H G M, van Duijn, C M & de Boer, A 2004, 'Pharmacoeconomic evaluation of testing for angiotensinconverting enzyme genotype before starting ß-hydrocy-ß-methylglutaryl coenzyme A reductase inhibitor therapy in men', Pharmacogenetics, vol. 14, pp. 53-60.